{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:57Z","timestamp":1767135117919,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":47,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd000969","type":"reference-entry","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T22:31:33Z","timestamp":1069367493000},"source":"Crossref","is-referenced-by-count":36,"title":["Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia"],"prefix":"10.1002","author":[{"given":"Helle Krogh","family":"Johansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C","family":"G\u00f8tzsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2000,7,24]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD000969-BIB1|cit1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/jac\/33.3.603","article-title":"A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies","volume":"33","author":"Caillot","year":"1994","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD000969-BIB2|cit2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD000969-BIB3|cit3","series-title":"The Tenth International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, 21-24 June 1998. International Immunocompromised Host Society","first-page":"Abstract 100","article-title":"Ambisome compared with amphotericin B deoxycholate in the treatment of neutropenia-associated invasive fungal infections","author":"Leenders","year":"1998"},{"key":"10.1002\/14651858.CD000969-BIB4|cit4","series-title":"Trends in Invasive Fungal Infections 4. Final Programme and Abstract Book, November 5-8, 1997, Barcelona, Spain","first-page":"54 (P-6)","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B in the treatment of neutropenia-associated invasive fungal infections","author":"Leenders","year":"1997"},{"key":"10.1002\/14651858.CD000969-BIB5|cit5","first-page":"336 (P1356)","article-title":"AmBisome 5 mg\/kg versus conventional amphotericin B (AmB) 1 mg\/kg in the treatment of neutropenia associated invasive aspergillosis","volume":"3 Suppl 2","author":"Leenders","year":"1997","journal-title":"Clinical Microbiology and Infection"},{"issue":"4","key":"10.1002\/14651858.CD000969-BIB7|cit6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/30.4.535","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients [see comments]","volume":"30","author":"Moreau","year":"1992","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD000969-BIB6|cit7","series-title":"Proceedings of the Annual Meeting of the American Society of Clinical Oncology","first-page":"380 (abstract 1","article-title":"Amphotericin B mixed with IntralipidR: reduction of nephrotoxicity in neutropenic patients","author":"Moreau","year":"1992"},{"issue":"6","key":"10.1002\/14651858.CD000969-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1128\/AAC.43.6.1417","article-title":"Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion","volume":"43","author":"Nath","year":"1999","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD000969-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1128\/AAC.43.6.1445","article-title":"Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients","volume":"43","author":"Nucci","year":"1999","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"12","key":"10.1002\/14651858.CD000969-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1177\/106002809502901201","article-title":"Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia","volume":"29","author":"Pascual","year":"1995","journal-title":"Annals of Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD000969-BIB11|cit11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD000969-BIB12|cit12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00043426-200005000-00009","article-title":"Use of amphotericin B colloidal dispersion in children","volume":"22","author":"Sandler","year":"2000","journal-title":"Journal of Pediatric Hematology\/Oncology: official journal of the American Society of Pediatric Hematology\/Oncology"},{"issue":"7155","key":"10.1002\/14651858.CD000969-BIB14|cit13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/bmj.317.7155.379","article-title":"Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study","volume":"317","author":"Schoffski","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000969-BIB13|cit14","first-page":"305 (P1237)","article-title":"No evidence of improved toxicity of amphotericin B in intralipid: results of a confirmatory randomized phase II-trial","volume":"3 Suppl 2","author":"Sch\u00f6ffski","year":"1997","journal-title":"Clinical Microbiology and Infection. Abstracts of 8th European Congress of Clinical Microbiology and Infectious Diseases. Lausanne, Switzerland, May 25-28, 1997."},{"issue":"5","key":"10.1002\/14651858.CD000969-BIB15|cit15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0609.2004.00239.x","article-title":"Low-dose amphotericin B lipid complex versus conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial","volume":"72","author":"Subira","year":"2004","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD000969-BIB17|cit16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/49.suppl_1.81","article-title":"Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"49 Suppl 1","author":"Cagnoni","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD000969-BIB16|cit17","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"18","author":"Cagnoni","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD000969-BIB18|cit18","first-page":"S3 (abstract 10","article-title":"A randomized, double-blind trial of ambisome (liposomal amphotericin B) versus Amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"78 Suppl 1","author":"Walsh","year":"1999","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD000969-BIB19|cit19","unstructured":"Walsh TJ Bodensteiner D Hiemenz J Thaler S Greenberg RN Arndt C et al The mycoses study group (MSG) and the empirical antifungal study group A randomised, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients Abstracts in Clinical Trials of Antimicrobials & Unique and Instructive Clinical Observations. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997, September 28-October 1, Toronto, Canada. 381 (Poster LM-90)"},{"issue":"10","key":"10.1002\/14651858.CD000969-BIB20|cit20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD000969-BIB21|cit21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America"},{"key":"10.1002\/14651858.CD000969-BIB22|cit22","series-title":"35th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"330 (LM21)","article-title":"Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invesive candidiasis: a prospective, randomized, multicenter trial","author":"Anaissie","year":"1995"},{"key":"10.1002\/14651858.CD000969-BIB23|cit23","series-title":"The Tenth International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, 21-24 June 1998. International Immunocompromised Host Society","first-page":"Abstract 091","article-title":"A double-blind, randomized controlled trial of Amphocil (ABCD) versus amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients","author":"Bowden","year":"1998"},{"issue":"4","key":"10.1002\/14651858.CD000969-BIB24|cit24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD000969-BIB25|cit25","series-title":"Trends in invasive fungal infections 5, Malta, 14-16 Oct","first-page":"128 (P6.08)","article-title":"Ambisome treatment for empiric treatment of fungal infections in haematology","author":"Richard","year":"1999"},{"issue":"11-12","key":"10.1002\/14651858.CD000969-BIB26|cit26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1439-0507.2001.00706.x","article-title":"Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study","volume":"44","author":"Uhlenbrock","year":"2001","journal-title":"Mycoses"},{"key":"10.1002\/14651858.CD000969-BIB27|cit27","first-page":"1154","article-title":"Liposomal amphotericin B for fever and neutropenia (letter)","volume":"341","author":"Winston","year":"1999","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD000969-BIB28|cit28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/08880019209018337","article-title":"Conventional versus liposomal amphotericin B in immunosuppressed children [letter]","volume":"9","author":"Zoubek","year":"1992","journal-title":"Pediatric Hematology and Oncology"},{"key":"10.1002\/14651858.CD000969-BIB29|cit29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/01621459.1989.10478782","article-title":"An assessment of publication bias using a sample of published clinical trials","volume":"84","author":"Berlin","year":"1989","journal-title":"Journal of the American Statistical Association"},{"key":"10.1002\/14651858.CD000969-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44(10)","author":"Cornely","year":"2007","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD000969-BIB31|cit31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2288-6-40","article-title":"Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents","volume":"6","author":"Due","year":"2006","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD000969-BIB32|cit32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1086\/514504","article-title":"International conference for the development of a consensus on the management and prevention of severe candidal infections","volume":"25","author":"Edwards","year":"1997","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD000969-BIB33|cit33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1128\/AAC.36.1.172","article-title":"Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B","volume":"36","author":"Ellis","year":"1992","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD000969-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clinical Infectious Diseases"},{"issue":"7286","key":"10.1002\/14651858.CD000969-BIB35|cit35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.322.7286.579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial","volume":"322","author":"Eriksson","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000969-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJM199910073411512","article-title":"Liposomal amphotericin B for fever and neutropenia (letter)","volume":"341","author":"Fischer","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000969-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1136\/bmj.314.7089.1238","article-title":"Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia","volume":"314","author":"G\u00f8tzsche","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD000969-BIB38|cit38","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000026","article-title":"Routine versus selective antifungal administration for control of fungal infections in patients with cancer","author":"G\u00f8tzsche","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000969-BIB39|cit39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/1097-0142(19910701)68:1<9::AID-CNCR2820680103>3.0.CO;2-U","article-title":"Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia","volume":"68","author":"Hiddemann","year":"1991","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD000969-BIB40|cit40","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1086\/513764","article-title":"1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America","volume":"25","author":"Hughes","year":"1997","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD000969-BIB41|cit41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/368312","article-title":"Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study","volume":"36","author":"Imhof","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD000969-BIB42|cit42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s005200050224","article-title":"Must we really fear toxicity of conventional amphotericin B in oncological patients?","volume":"7","author":"Mayer","year":"1999","journal-title":"Support Care Cancer"},{"key":"10.1002\/14651858.CD000969-BIB43|cit43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2141.1998.00600.x","article-title":"Antifungal therapy in \"bone marrow failure\"","volume":"100","author":"Richardson","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD000969-BIB44|cit44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1469-0691.1997.tb00615.x","article-title":"Do the new lipid formulations of amphotericin B really work?","volume":"3","author":"Tang","year":"1997","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1002\/14651858.CD000969-BIB45|cit45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/joim.1997.242.s740.89","article-title":"Antifungal treatment in patients with cancer","volume":"242 Suppl 740","author":"Viscoli","year":"1997","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD000969-BIB46|cit46","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000969","article-title":"Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia","author":"Johansen","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000969-BIB47|cit47","article-title":"Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia","author":"Johansen","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd000969.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,9,4]],"date-time":"2014-09-04T00:00:00Z","timestamp":1409788800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T16:58:41Z","timestamp":1628528321000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD000969"}},"subtitle":[],"editor":[{"given":"Helle Krogh","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2000,7,24]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000969","relation":{},"subject":[],"published":{"date-parts":[[2000,7,24]]}}}